The VASCEPA® difference.

VASCEPA is different than other prescription medications.


Earlier generation, FDA-approved treatment options for very high triglycerides are associated with potential unwanted side effects including muscle pain and a significant increase in bad cholesterol (LDL-C).

There's only one VASCEPA.

VASCEPA is the first and only pure EPA prescription Omega-3* treatment approved by the FDA to lower very high triglycerides (without raising bad cholesterol).

Learn More

*Vascepa 1-gram capsules contain 1 gram of icosapent ethyl, a form of the
unique Omega-3 fatty acid known as EPA, and inactive ingredients.
In MARINE trial, on average, along with diet changes, adults with very high triglycerides experienced a 33% reduction without raising LDL-C vs. placebo. Individual results may vary.

VASCEPA, along with diet, is clinically proven to lower very high triglycerides in adults by 33% without raising bad cholesterol.

*Vascepa 1-gram capsules contain 1 gram of icosapent ethyl, a form of the unique Omega-3 fatty acid known as EPA, and inactive ingredients.
†In MARINE trial, on average, along with diet changes, adults with very high triglycerides experienced a 33% reduction without raising LDL-C vs. placebo. Individual results may vary.

VASCEPA (icosapent ethyl)
is different from
Lovaza® (omega-3-acid ethyl esters)


This chart contains FDA-approved prescription product information related to patients with very high triglycerides taking 4 grams per day.

No head to head trials have been conducted between VASCEPA and other prescription Omega-3s, such as Lovaza.

VASCEPA1
(icosapent ethyl)
Lovaza2-7
(omega-3-acid ethyl esters)
Clinically proven and FDA-approved to lower very high triglycerides1-2 Check Mark Check Mark
Contains only one active ingredient:
pure EPA Omega-3
Check Mark
Not shown to raise bad cholesterol (LDL-C)1-2 Check Mark
Doesn't require additional monitoring of bad cholesterol Check Mark
No associated increase in frequency of atrial fibrillation or flutter (irregular or rapid heart rate)1-2 Check Mark
No reported "burping, upset stomach, or a change in sense of taste"1-7 Check Mark

Lovaza should not be substituted for VASCEPA.
If your pharmacist suggests switching, talk with your doctor first.

  1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma, Inc; 2017.
  2. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
  1. Omega-3 acid ethyl esters Prescribing Information. Amneal Pharmaceuticals of New York LLC; 2016.
  2. Omega-3 acid ethyl esters Prescribing Information. Apotex Inc; 2014.
  3. Omega-3 acid ethyl esters Prescribing Information. Par Pharmaceutical Inc; 2017.
  4. Omega-3 acid ethyl esters Prescribing Information. Strides Pharma Global Pte Ltd; 2017.
  5. Omega-3 acid ethyl esters Prescribing Information. Teva Pharmaceuticals; 2016.

History of other available FDA-approved drug therapies for patients with very high triglycerides


Fenofibrates and nicotinic acid are two other classes of drug therapy used to treat patients with very high triglyceride levels. Examples of fenofibrates are: TriCor8 and Trilipix.9 Examples of nicotinic acid are: Niacor10 and Niaspan.11

These earlier generation classes of triglyceride lowering therapies, initially launched in 1970s and 1950s, respectively, are not recommended by the FDA for use with statin therapy.

Use of fenofibrates, when used to treat patients with very high triglycerides, resulted in increased bad cholesterol levels in many patients.8,9

Read more

Potential adverse side effects of fenofibrates include potential increased muscle pain and increased risk of gallstones.8,9 Potential adverse side effects of nicotinic acid-class drugs include potential increased muscle pain and flushing.10,11

No head-to-head studies have been conducted to compare the effects of VASCEPA to these other therapies.

The information above regarding VASCEPA, Lovaza, fenofibrates and nicotinic acid therapies is from the FDA approved labels for these drugs. Label comparisons can be misleading based on numerous factors, including different timeframes and baseline lipid levels and diets of patients enrolled in the underlying studies of each therapy. For example:

• Higher baseline levels of triglyceride levels often result in greater percentage reduction in triglyceride levels when treated and baseline triglyceride levels were generally higher in studies of very high triglyceride patients for Lovaza and fenofibrates.8-11

• Registration studies for Lovaza, fenofibrates and nicotinic acid therapies in patients with very high triglycerides were conducted in the 1990s or earlier with none of the patients in the studies on statin therapy. Had the baseline triglyceride levels been impacted by statin therapy, the results may have been different.8-11

Potential adverse side effects of fenofibrates include potential increased muscle pain and increased risk of gallstones.8,9 Potential adverse side effects of nicotinic acid-class drugs include potential increased muscle pain and flushing.10,11

No head-to-head studies have been conducted to compare the effects of VASCEPA to these other therapies.

The information above regarding VASCEPA, Lovaza, fenofibrates and nicotinic acid therapies is from the FDA approved labels for these drugs. Label comparisons can be misleading based on numerous factors, including different timeframes and baseline lipid levels and diets of patients enrolled in the underlying studies of each therapy. For example:

• Higher baseline levels of triglyceride levels often result in greater percentage reduction in triglyceride levels when treated and baseline triglyceride levels were generally higher in studies of very high triglyceride patients for Lovaza and fenofibrates.8-11

• Registration studies for Lovaza, fenofibrates and nicotinic acid therapies in patients with very high triglycerides were conducted in the 1990s or earlier with none of the patients in the studies on statin therapy. Had the baseline triglyceride levels been impacted by statin therapy, the results may have been different.8-11

• Higher baseline levels of triglyceride levels often result in greater percentage reduction in triglyceride levels when treated and baseline triglyceride levels were generally higher in studies of very high triglyceride patients for Lovaza and fenofibrates.8-11

• Registration studies for Lovaza, fenofibrates and nicotinic acid therapies in patients with very high triglycerides were conducted in the 1990s or earlier with none of the patients in the studies on statin therapy. Had the baseline triglyceride levels been impacted by statin therapy, the results may have been different.8-11

Patients should consult with their physicians for further information.

Join The VASCEPA Clear Path Program.


Sign up today to receive motivational tips and useful information to support you on a Clear Path toward lowering very high triglycerides.

REGISTER NOW
 
Exit
Exit

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies.
If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

INDICATION

WHAT IS VASCEPA?

VASCEPA is a prescription medicine used along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats) in adults.

  • It is not known if VASCEPA changes your risk of having inflammation of your pancreas (pancreatitis).
  • It is not known if VASCEPA prevents you from having a heart attack or stroke.
  • It is not known if VASCEPA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

WHO SHOULD NOT TAKE VASCEPA?

  • Do not take VASCEPA if you are allergic to icosapent ethyl or any of the ingredients in VASCEPA.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF VASCEPA?

  • It is not known if people who are allergic to fish or shellfish are also allergic to VASCEPA.
  • If you have liver problems and are taking VASCEPA, your doctor should do blood tests during treatment.
  • The most common side effect of VASCEPA is joint pain. Talk to your doctor for medical advice about side effects.

As with all drugs, you may experience a serious side effect when taking VASCEPA.

You may report side effects by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Tell your doctor if you take medicines that affect your blood clotting (anticoagulants or blood thinners).

Take VASCEPA capsules whole. Do not break, crush, dissolve, or chew VASCEPA capsules before swallowing.

For more information on VASCEPA, click here to see the full Patient Information or call 1-855-VASCEPA (1-855-827-2372).